HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus’s replication, providing long-term protection. If this yearly injection is approved and widely implemented, it could mark a major shift in global HIV prevention efforts. It has the potential to significantly reduce new HIV infections, particularly in communities with high transmission rates.Scientists develop yearly HIV injection
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus’s replication, providing long-term protection. If this yearly injection is approved and widely implemented, it could mark a major shift in global HIV prevention efforts. It has the potential to significantly reduce new HIV infections, particularly in communities with high transmission rates.